A report on the proposed Division 296 tax, being an additional 15 per cent tax to future earnings of member balances above $3 ...
Soleno Therapeutics faces scrutiny over Vykat safety after a patient death. Click here to find out why I rate SLNO a Hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback